Prognostic Influence of B-Sort Natriuretic Peptide on Lengthy-Time period Scientific Outcomes in Sufferers with Non-ST-Phase Elevation Acute Myocardial Infarction With out Creatine Kinase Elevation
Though B-type natriuretic peptide (BNP) has steadily gained recognition as an indicator in danger stratification for sufferers with acute myocardial infarction (AMI), the prognostic impression on long-term scientific outcomes in sufferers with non-ST-segment elevation acute myocardial infarction (NSTEMI) with out creatine kinase (CK) elevation stays unclear.This potential multicenter research assessed 3,283 consecutive sufferers with AMI admitted to 28 establishments in Japan between 2012 and 2014.
We analyzed 218 sufferers with NSTEMI with out CK elevation (NSTEMI-CK) for whom BNP was obtainable. Within the NSTEMI-CK group, sufferers had been assigned to high- and low-BNP teams in keeping with BNP values (cut-off BNP, 100 pg/mL). The main endpoint was outlined as a composite of all-cause demise, non-fatal myocardial infarction, non-fatal stroke, cardiac failure, and pressing revascularization for unstable angina as much as Three years.
Major endpoints had been noticed in 60 (33.3%) occasions amongst sufferers with NSTEMI-CK. Kaplan-Meier evaluation revealed a considerably greater occasion charge for main endpoints amongst sufferers with excessive BNP (log-rank P < 0.001). After adjusting for covariates, the next BNP stage was considerably related with long-term scientific outcomes in NSTEMI-CK (adjusted hazard ratio, 4.86; 95% confidence interval, 2.18-12.44; P < 0.001).The BNP focus is related to antagonistic long-term scientific outcomes amongst sufferers with NSTEMI-CK who’re thought-about low danger. Cautious scientific administration could also be warranted for secondary prevention in sufferers with NSTEMI-CK with excessive BNP ranges.
Description: A polyclonal antibody against TAT. Recognizes TAT from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000
Description: A polyclonal antibody against TAT. Recognizes TAT from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF; Recommended dilution: WB:1:500-1:5000, IF:1:50-1:200
Description: A polyclonal antibody against TAT. Recognizes TAT from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100
Description: A polyclonal antibody for detection of TAT from Human, Mouse, Rat. This TAT antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human TAT
Description: A polyclonal antibody for detection of TAT from Human, Mouse, Rat. This TAT antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human TAT
Description: A polyclonal antibody for detection of TAT from Human, Mouse, Rat. This TAT antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human TAT
Description: This nuclear gene encodes a mitochondrial protein tyrosine aminotransferase which is present in the liver and catalyzes the conversion of L-tyrosine into p-hydroxyphenylpyruvate. Mutations in this gene cause tyrosinemia (type II, Richner-Hanhart syndrome), a disorder accompanied by major skin and corneal lesions, with possible mental retardation. A regulator gene for tyrosine aminotransferase is X-linked.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Canine C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Canine C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Rat C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Rat C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: Sox2, also known as sex determining region Y (SRY)-box 2, belongs to a diverse family of structurally-related transcription factors whose primary structure contains a 79-residue DNA-binding domain, called high mobility group (HMG) box. It plays an essential role in maintaining the pluripotency of embryonic stem cells (ESC) and determination of cell fate. Microarray analysis showed that Sox2 regulates the expression of multiple genes involved in embryonic development including FGF-4, YES1 and ZFP206. Sox2 acts as a transcriptional activator after forming a ternary complex with Oct3/4 and a conserved non-coding DNA sequence (CNS1) located approximately 2 kb upstream of the RAX promoter. The introduction of Sox2, Oct4, Myc, and Klf4, into human dermal fibroblasts isolated from a skin biopsy of a healthy research fellow was sufficient to confer a pluripotent state upon the fibroblast genome. The reprogrammed cells thus obtained resemble ESC in morphology, gene expression, and in the capacity to form teratomas in immune-deficient mice. Sox2 and other transcription factors have been introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors and other nuclear proteins into primary as well as transformed cells. Recombinant human Sox2-TAT expressed in E. coli is a 36 kDa protein containing 330 amino-acid residues, including the 317 residues of full-length Sox2 and a 13-residue C-terminal TAT peptide (GGYGRKKRRQRRR).
Description: Sox2, also known as sex determining region Y (SRY)-box 2, belongs to a diverse family of structurally-related transcription factors whose primary structure contains a 79-residue DNA-binding domain, called high mobility group (HMG) box. It plays an essential role in maintaining the pluripotency of embryonic stem cells (ESC) and determination of cell fate. Microarray analysis showed that Sox2 regulates the expression of multiple genes involved in embryonic development including FGF-4, YES1 and ZFP206. Sox2 acts as a transcriptional activator after forming a ternary complex with Oct3/4 and a conserved non-coding DNA sequence (CNS1) located approximately 2 kb upstream of the RAX promoter. The introduction of Sox2, Oct4, Myc, and Klf4, into human dermal fibroblasts isolated from a skin biopsy of a healthy research fellow was sufficient to confer a pluripotent state upon the fibroblast genome. The reprogrammed cells thus obtained resemble ESC in morphology, gene expression, and in the capacity to form teratomas in immune-deficient mice. Sox2 and other transcription factors have been introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors and other nuclear proteins into primary as well as transformed cells. Recombinant human Sox2-TAT expressed in E. coli is a 36 kDa protein containing 330 amino-acid residues, including the 317 residues of full-length Sox2 and a 13-residue C-terminal TAT peptide (GGYGRKKRRQRRR).
Description: TIGAR is a p53-inducible enzyme that catalyzes the hydrolysis of fructose-2-6 bisphosphate (F-2-6-BP) to fructose-6-phosphate and inorganic phosphate. F-2-6-BP is a powerful activator of 6-phosphofructose-1 kinase, the rate limiting enzyme of glycolysis. By lowering the intracellular level of F-2-6-BP, TIGAR expression leads to increased glucose processing via the pentose phosphate pathway, the major cellular source for NADPH. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors and other intracellular proteins into primary as well as transformed cells. Recombinant human TIGAR-TAT expressed in E. coli is a 36 kDa protein containing 284 amino-acid residues, including the 271 residues of full-length TIGAR fused to a 13-residue C-terminal peptide containing the TAT transduction domain (GGYGRKKRRQRRR).
Description: TIGAR is a p53-inducible enzyme that catalyzes the hydrolysis of fructose-2-6 bisphosphate (F-2-6-BP) to fructose-6-phosphate and inorganic phosphate. F-2-6-BP is a powerful activator of 6-phosphofructose-1 kinase, the rate limiting enzyme of glycolysis. By lowering the intracellular level of F-2-6-BP, TIGAR expression leads to increased glucose processing via the pentose phosphate pathway, the major cellular source for NADPH. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors and other intracellular proteins into primary as well as transformed cells. Recombinant human TIGAR-TAT expressed in E. coli is a 36 kDa protein containing 284 amino-acid residues, including the 271 residues of full-length TIGAR fused to a 13-residue C-terminal peptide containing the TAT transduction domain (GGYGRKKRRQRRR).
Description: KLF4 is a member of the Kruppel-like factor (KLF) family of zinc finger transcription factors. Members of this family have in common 3 contiguous C2H2-type zinc fingers at the carboxyl terminus that comprise the DNA-binding domain. KLF4 is highly expressed in skin and gut epithelial tissues, but is also found in various other cells and tissues, including vascular endothelial cells, lymphocytes, lung, and testis. It is an important regulator of the cell cycle, transcription, and cell differentiation. Together with Sox2, Oct4, and cMyc, KLF4 can induce the reprogramming of primary human fibroblasts to a pluripotent state. KLF4 and other transcription factors can be introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors into primary as well as transformed cells. Recombinant Human KLF4-TAT is a 483 amino acid protein, including a 13-residue C-terminal TAT peptide, with a calculated molecular weight of 51.7kDa. Recombinant Human KLF4-TAT is a mixture of the expected sequence beginning at Met1 and a truncated isoform beginning at Tyr54. Due to post-translational modifications, SDS-PAGE gel shows bands at approximately 72 and 66kDa, under reduced conditions.
Description: KLF4 is a member of the Kruppel-like factor (KLF) family of zinc finger transcription factors. Members of this family have in common 3 contiguous C2H2-type zinc fingers at the carboxyl terminus that comprise the DNA-binding domain. KLF4 is highly expressed in skin and gut epithelial tissues, but is also found in various other cells and tissues, including vascular endothelial cells, lymphocytes, lung, and testis. It is an important regulator of the cell cycle, transcription, and cell differentiation. Together with Sox2, Oct4, and cMyc, KLF4 can induce the reprogramming of primary human fibroblasts to a pluripotent state. KLF4 and other transcription factors can be introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors into primary as well as transformed cells. Recombinant Human KLF4-TAT is a 483 amino acid protein, including a 13-residue C-terminal TAT peptide, with a calculated molecular weight of 51.7kDa. Recombinant Human KLF4-TAT is a mixture of the expected sequence beginning at Met1 and a truncated isoform beginning at Tyr54. Due to post-translational modifications, SDS-PAGE gel shows bands at approximately 72 and 66kDa, under reduced conditions.
Description: Nanog is a regulatory protein that is associated with undifferentiated pluripotent cells. The expression of Nanog, which is suppressed in all adult tissues, is restricted to embryonic stem cells and to certain pluripotent cancer cells. Decreased expression of Nanog is strongly correlated with cell differentiation. Nanog, most likely, acts as an intracellular regulator, which helps maintain pluripotency and self renewal via a STAT3 independent pathway. The introduction of Nanog, along with Sox2, Oct4, Lin28, into primary human fibroblasts was sufficient to confer a pluripotent state upon the fibroblast genome. The reprogrammed cells thus obtained resemble ESC in morphology and gene expression. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors into primary as well as transformed cells. Recombinant human Nanog-TAT is a 36.1 kDa protein, which is synthesized as a 304 amino acid polypeptide plus a 13- residue C-terminal TAT peptide.
Description: Nanog is a regulatory protein that is associated with undifferentiated pluripotent cells. The expression of Nanog, which is suppressed in all adult tissues, is restricted to embryonic stem cells and to certain pluripotent cancer cells. Decreased expression of Nanog is strongly correlated with cell differentiation. Nanog, most likely, acts as an intracellular regulator, which helps maintain pluripotency and self renewal via a STAT3 independent pathway. The introduction of Nanog, along with Sox2, Oct4, Lin28, into primary human fibroblasts was sufficient to confer a pluripotent state upon the fibroblast genome. The reprogrammed cells thus obtained resemble ESC in morphology and gene expression. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors into primary as well as transformed cells. Recombinant human Nanog-TAT is a 36.1 kDa protein, which is synthesized as a 304 amino acid polypeptide plus a 13- residue C-terminal TAT peptide.
Description: Lin28 is a RNA-binding protein that belongs to a diverse family of structurally-related transcription factors. Lin28 is found abundantly in embryonic stem cells (ESCs), and to a lesser extent in placenta and testis. Lin28 has been shown to block let-7 microRNA processing and maturation, a necessary step in the differentiation of stem cells and certain cancer cell lines. Together with Sox2, Oct4, and Nanog, Lin28 can induce the reprogramming of primary human fibroblasts to a pluripotent state. Lin28 and other regulatory proteins can be introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing proteins into primary as well as transformed cells. Recombinant human Lin28-TAT is a 24.4 kDa protein containing 222 amino acid residues, including 13- residue C-terminal TAT peptide.
Description: Lin28 is a RNA-binding protein that belongs to a diverse family of structurally-related transcription factors. Lin28 is found abundantly in embryonic stem cells (ESCs), and to a lesser extent in placenta and testis. Lin28 has been shown to block let-7 microRNA processing and maturation, a necessary step in the differentiation of stem cells and certain cancer cell lines. Together with Sox2, Oct4, and Nanog, Lin28 can induce the reprogramming of primary human fibroblasts to a pluripotent state. Lin28 and other regulatory proteins can be introduced into cells by DNA transfection, viral infection, or microinjection. Protein transduction using TAT fusion proteins represents an alternative methodology for introducing proteins into primary as well as transformed cells. Recombinant human Lin28-TAT is a 24.4 kDa protein containing 222 amino acid residues, including 13- residue C-terminal TAT peptide.
Cruzioseptins, antibacterial peptides from Cruziohyla calcarifer pores and skin, as promising leishmanicidal brokers
Screenings of pure merchandise have considerably contributed to the invention of novel leishmanicidal brokers. On this research, three identified cruzioseptins-antibacterial peptides from Cruziohyla calcarifer skin-were synthesized and evaluated in opposition to promastigotes and amastigotes levels of Leishmania (L.) amazonensis and L. (V.) braziliensis. EC50 ranged from 9.17 µM to 74.82 µM, being cruzioseptin-1 probably the most energetic and selective compound, with selectivity index > 10 for each promastigotes and amastigotes of L. (V.) braziliensis.
In vitro infections incubated with cruzioseptins at 50 µM confirmed as much as ∼86% discount within the amastigote quantity. Cruzioseptins had been capable of destabilize the parasite’s cell membrane, permitting the incorporation of a DNA-fluorescent dye. Our information additionally demonstrated that hydrophobicity and cost look like advantageous options for enhancing parasiticidal exercise. Antimicrobial cruzioseptins are appropriate candidates and different molecules that deserve additional in vivo investigation specializing in the event of novel antileishmanial therapies.
Examine on Adenovirus An infection in vitro with Nanoself-Assembling Peptide as Scaffolds for 3D Tradition
Objective: To assemble a three-dimensional (3D) tradition mannequin of adenovirus in vitro utilizing the nanoself-assembling peptide RADA16-I as a 3D cell tradition scaffold mixed with virology experimental expertise to offer a novel analysis technique for virus isolation and tradition, pathogenesis analysis, antiviral drug screening and vaccine preparation.
Strategies: The nanoself-assembling peptide RADA16-I used to be used as a 3D scaffold materials for 293T cell tradition, and adenovirus was cultured within the cells. The expansion, morphological traits and pathological results of 3D-cultured 293T cells after adenovirus an infection had been noticed with an inverted microscope and MTS. The proliferation of adenovirus in 293T cells was noticed by TEM and detected by qPCR. The degrees of TNF-α and IL-Eight secreted by adenovirus-infected 293T cells within the RADA16-I 3D tradition system had been detected by ELISA.
Outcomes: The 293T cells grew properly within the RADA16-I 3D tradition system for a protracted time frame. The adenovirus an infection continued for a very long time with a number of proliferation peaks, which carefully resembled these of in vivo infections. The adenovirus virions amplified within the 3D system remained infectious. There have been a number of secretion peaks of TNF-α and IL-Eight secretion ranges in adenovirus-infected 293T cells cultured in 3D tradition methods.
Conclusion: The nanoself-assembling peptide RADA16-I can be utilized as a 3D scaffold for adenovirus isolation, tradition and analysis. The 3D tradition system exhibits extra lifelike in vivo results than two-dimensional (2D) tradition.
Auto-reactivity in opposition to intestine bacterial peptides in sufferers with late-onset diabetes
The depletion of intestine mucosal barrier allows publicity of intestine microbes/intestine microbial merchandise to the host mucosal immunity which can enhance the chance of metabolic/inflammatory problems. These immune responses can result in the event of gentle autoimmunity to metabolic peptides coming from intestine micro organism and will lead to metabolic ailments like late-onset diabetes (LOD).
Within the current research, we recognized host sera cross-reactivity with intestine bacterial peptides much like host proteins. The interplay between diabetic sera and intestine peptides was detected by enzyme-linked immunosorbent assay (ELISA) and outcomes had been confirmed utilizing floor plasmon resonance (SPR). The ELISA assay confirmed the next stage of serum cross-reactivity in LOD sufferers as in comparison with non-diabetic controls in opposition to three peptides (P-5, P-9, and P-13). SPR evaluation confirmed binding-affinity in opposition to P-5 and P-13. Additionally, a big correlation was noticed between inflammatory markers and P-5. This research demonstrates that intestine well being is vital not just for intestinal ailments but in addition for a number of late-onset ailments, like, diabetes.
Rat Interferon Regulatory Factor 4 (IRF4) ELISA Kit
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:1000-1:2000, WB:1:200-1:1000
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:1000-1:2000, WB:1:200-1:1000
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC
Description: IRF4 Antibody: Interferons (IFNs) are involved in a multitude of immune interactions during viral infections and play a major role in both the induction and regulation of innate and adaptive antiviral mechanisms. During infection, host-virus interactions signal downstream molecules such as transcription factors such as IFN regulatory factor-3 (IRF3) which can act to stimulate transcription of IFN-alpha/beta genes. Another member, IRF7 has been shown to play a role in the transcriptional activation of virus-inducible cellular genes, including interferon beta chain genes. IRF4 expression is tightly regulated in resting primary T cells and plays an essential role in the homeostasis and function of mature lymphocytes. IRF4 is induced by Toll-like receptor (TLR) activation and acts as a negative regulator of TLR signaling.
Description: IRF4 Antibody: Interferons (IFNs) are involved in a multitude of immune interactions during viral infections and play a major role in both the induction and regulation of innate and adaptive antiviral mechanisms. During infection, host-virus interactions signal downstream molecules such as transcription factors such as IFN regulatory factor-3 (IRF3) which can act to stimulate transcription of IFN-alpha/beta genes. Another member, IRF7 has been shown to play a role in the transcriptional activation of virus-inducible cellular genes, including interferon beta chain genes. IRF4 expression is tightly regulated in resting primary T cells and plays an essential role in the homeostasis and function of mature lymphocytes. IRF4 is induced by Toll-like receptor (TLR) activation and acts as a negative regulator of TLR signaling.
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human IRF4 . This antibody is tested and proven to work in the following applications:
Description: The protein encoded by this gene belongs to the IRF (interferon regulatory factor) family of transcription factors, characterized by an unique tryptophan pentad repeat DNA-binding domain. The IRFs are important in the regulation of interferons in response to infection by virus, and in the regulation of interferon-inducible genes. This family member is lymphocyte specific and negatively regulates Toll-like-receptor (TLR) signaling that is central to the activation of innate and adaptive immune systems. A chromosomal translocation involving this gene and the IgH locus, t(6;14)(p25;q32), may be a cause of multiple myeloma. Alternatively spliced transcript variants have been found for this gene.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Canine C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Canine C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Human C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Rat C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Rat C-Peptide in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human IRF4 (C-Terminus). This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human IRF4 (C-Term). This antibody is tested and proven to work in the following applications:
Description: Description of target: Transcriptional activator. Binds to the interferon-stimulated response element (ISRE) of the MHC class I promoter. Binds the immunoglobulin lambda light chain enhancer, together with PU.1. Probably plays a role in ISRE-targeted signal transduction mechanisms specific to lymphoid cells. Involved in CD8+ dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF4 and activation of genes.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 3.9 pg/mL
Description: A Monoclonal antibody against Human IRF4 (clone 2F2). The antibodies are raised in Mouse and are from clone 2F2. This antibody is applicable in WB and IHC-P, E
Description: A Monoclonal antibody against Human IRF4 (monoclonal) (M02). The antibodies are raised in mouse and are from clone 2F2. This antibody is applicable in WB and IHC, E
Description: A Monoclonal antibody against Human IRF4 (monoclonal) (M05). The antibodies are raised in mouse and are from clone 2D1. This antibody is applicable in WB and IF, E
door 
